SHIV/中国恒河猴模型的建立及在艾滋病疫苗免疫保护效果评价中的应用研究
|
摘要
目前,艾滋病已成为影响人类健康的最严重的传染性疾病之一。世界各国严峻的流行形式迫切需要研制出安全有效的预防性艾滋病疫苗。疫苗的安全性、有效性以及免疫策略需要在合适的动物模型中进行评价。其中,SHW/印度恒河猴艾滋病模型是应用最为广泛的动物模型之一。
包含中国HIV-1 CRF07 BC主要流行株基因CCR5嗜性的致病性SHIV/中国恒河猴艾滋病模型在基于中国HIV-1主要流行株设计的艾滋病疫苗免疫保护效果评价中可以发挥非常重要的作用。SHIV-XJ02170感染性分子克隆是以B亚型强毒株SHIV-KB9基因为框架重组入中国CRF07 BC亚型HIV-1主要流行株env基因构建而成,本研究将SHIV-XJ02170连同Ruth M Ruprecht教授惠赠的另一株包含CRF07 BC亚型HIV-1 env的SHIV-CN97001分别在中国恒河猴体内快速传代。经过近4年的连续猴体传代和长期适应后,通过病毒载量和外周血CD4~+T淋巴细胞计数分析未发现致病性强毒株的出现。不过,两株SHIV病毒在猴体传代过程中表现出病毒毒力增强的特点。其中,SHIV-CN97001在前3代中病毒复制能力持续升高。更为重要的是,SHIV-XJ02170传代中的两只动物表现出潜伏期稳定的低水平病毒血症过程。
为了分析SHIV-CN97001和SHIV-XJ02170传代过程中序列变异特点,扩增各代动物急性期病毒载量峰值时间点病毒RNA Gp120克隆序列并分析病毒准种之间的基因离散率和遗传多样性。SHIV-CN97001传代过程中基因距离表现出先升后降的趋势,其中第三代动物中基因离散率和遗传多样性最显著。SHIV-XJ02170传代中的408动物体内病毒相对于原始序列基因离散率在适应过程中持续上升。分析发现各代动物基因离散率和病毒复制能力之间存在相关性。基因多态性分析发现两株SHIV病毒Gp120 V3区在传代过程中均最为保守。基于V3区关键氨基酸位点分析发现所有RNA克隆序列均利用CCR5作为辅助受体,传代过程中未发生改变。总体而言,SHIV-CN97001和SHIV-XJ02170传代过程中Gp120基因距离未出现明显上升,并且每代动物传代早期出现典型的“瓶颈效应”。按照Mullins教授提出的HIV-1感染后致病过程不同阶段基因距离变化理论分析,SHIV-XJ02170在第二代动物408体内目前已经处于感染的后期阶段。病毒准种基因变异分析可以部分解释两株SHIV病毒在中国恒河猴体内传代过程中未出现致病性强毒株的原因。
为建立致病性SHIV-KB9/中国恒河猴艾滋病疫苗评价模型并比较SHIV-KB9在中国恒河猴和印度恒河猴体内致病模式的差异。7只Mamu-A~*01阴性的中国恒河猴静脉途径接种1-1000 MID_(50)剂量的SHIV-KB9并监测病毒载量、CD4/CD8比值、SHIV特异性抗体滴度以及病毒序列变异。在中国恒河猴中,SHIV-KB9表现出和文献报道的印度恒河猴中相同的三种致病模式。然而,SHIV-KB9在两亚种动物中的主要致病模式是不同的。另外,SHIV-KB9感染中国恒河猴后三种致病模式中病毒血症的特点与印度恒河猴是不同的。对比发现,病毒载量和CD4~+T细胞的维持能力与体液免疫反应相关。值得注意的是,在CD4~+T细胞显著下降的动物体内SHIV-KB9病毒准种的基因离散率和遗传多样性明显升高。SHIV-KB9在中国恒河猴体内表现出相对印度恒河猴致病过程进展更加缓慢的特点,这一特点更加接近HIV-1在人体的致病特点并更适合做为艾滋病疫苗的评价模型。另外,SHIV-CN97001和SHIV-KB9感染中国恒河猴后可以诱导针对SHIV-KB9的异源性和同源性免疫保护反应。因此,SHIV病毒成功感染中国恒河猴后继续进行SHIV-KB9二次攻毒试验在中国恒河猴艾滋病疫苗免疫保护效果评价中是不适合的。
为了控制艾滋病在中国的流行,本研究团队研制了包含中国CRF07_BC亚型主要流行毒株HIV-1 CN54 gag,pol,nef以及gp140基因的DNA疫苗和复制性天坛株重组痘苗病毒载体疫苗(rTV)。为了评价本疫苗的免疫源性和攻毒保护效果并分析DNA疫苗的初免效果,采用rTV单免和DNA/rTV联合免疫两种策略免疫12只中国恒河猴,并选用同源性SHIV-CN97001和异源性SHIV-KB9二次攻毒的方式分析疫苗的免疫保护效果。免疫和攻毒后,监测细胞和体液免疫反应以及病毒载量的变化。HIV特异性结合抗体滴度和IFN-γ分泌性T细胞免疫反应分别采用ELISA和ELISPOT方法分析,中和抗体滴度通过测定SHIV-KB9在TZM-bl细胞的感染能力进行分析。相比rTV单免组,DNA/rTV联合免疫组动物疫苗免疫后可以诱导10倍以上水平的IFN-γ分泌性T细胞免疫反应,但诱导的结合抗体和中和抗体滴度水平没有明显差异。两种免疫策略均可以在最后一次痘苗免疫9个月后诱导出很强的记忆性免疫反应。
同源性SHIV-CN97001病毒攻击后,rTV单免组全部4只动物均获得完全性保护的效果。然而,DNA/rTV联合免疫组3只动物中仅有1只动物获得完全性保护效果,其它2只动物获得部分性保护效果。10个月之后,两组中各挑选1只针对SHIV-CN97001完全性保护的动物进行异源性SHIV-KB9的二次病毒攻击。联合免疫组中M7动物通过病毒载量和血液传代分析依然保持完全性保护的效果,而rTV单免组M2动物仅获得部分性保护的效果,表现为急性期病毒载量峰值水平下降以及潜伏期病毒载量下降至低于最低检测限水平。分析发现在同源性SHIV-CN97001免疫保护方面中和抗体可能发挥了关键性作用,而在异源性SHIV-KB9免疫保护方面IFN-γ分泌性T细胞免疫反应和免疫保护密切相关。
DNA-复制性重组痘苗病毒艾滋病疫苗免疫中国恒河猴后提供有效且持续性的免疫反应,可以有效的保护动物抵抗同源性和异源性SHIV病毒的攻击。本研究可以对艾滋病疫苗的临床试验提供有效的参考数据。
Human immunodeficiency virus(HIV) infection and AIDS continue to be a growing problem for the world's population.The need to develop a safe and efficacious vaccine against HIV is more pressing than ever.
A pathogenic R5 simian-human immunodeficiency virus(SHIV) encoding genes of the predominant prevalent HIV-1 B'/C Recombinant(CRF07_BC) strain in China was highly desirable to study the role of HIV-1 envelopes in transmission and pathogenesis as well as to evaluate candidate AIDS vaccines in nonhuman primates. To this end,SHIV-XJ02170 and SHIV-CN97001 which also carrying CRF07_BC env, were adapted by serial passage in thirteen Chinese-origin Rhesus Macaques,separately. Up to now,there were no pathogenic viral strain obtained during in vivo passage by viral load and CD4/CD8 ratio analysis.But,it was revealed that the infectivity property of the two SHIVs enhanced during in vivo passage.The viral RNA load of third passage was highest during SHIV-CN97001 passage and two animals infected SHIV-XJ02170 had inclined setpoint viral load.
To identify variation in the gpl20 region of SHIV-CN97001 and SHIV-XJ02170 during passage,the fragments of gpl20 gene were amplified by RT-PCR from the plasma of infected animals at the peak viral load time point and the gene distances (divergence,diversity) were calculated using DISTANCE.The analysis revealed that the genetic distances of SHIV-CN97001 in the third passage animals were the highest and the gene divergence from founder strain in M408 serially inclined during SHIV-XJ02170 in vivo adaption.It had a relationship between viral divergence from the founder strain and viral replication ability.In the two SHIV constructs,the nucleic acid sequence of the V3 region was highly conservative and all the RNA clones were predicted to be using CCR5 co-receptor on the basis of the critical amino acids within V3 loop.These results showed that there was no significant increase in the genetic distance during SHIV-CN97001 and SHIV-XJ02170 passage,and the two SHIV gp120 gene evolved toward ancestral states upon transmission to a new host.But,the SHIV-XJ02170 virus in one of second passage animals(408) maybe has involved the late infection phase according to gene distance analysis.This could partly explain why there has no pathogenic viral strain obtained during in vivo passage.
To develop a SHIV-KB9/Chinese-origin rhesus macaques(Ch Rh) model for vaccine research and to compare the pathogenesis of SHIV-KB9 in Ch Rh with published reports from Indian-origin rhesus macaques(Ind Rh).Seven mamu-A*01 negative Ch Rh were inoculated intravenously with 1-1000 MID_(50) of SHIV-KB9.The monkeys were monitored by measured viral load,CD4,CD8,SHIV-specific antibody and virus genetic variation.In Ch Rh,SHIV-KB9 displayed three identical disease progression patterns,compared to what observed in Ind Rh.However,the primary pattern was not same for the two subspecies.The level of plasma viremia differed in SHIV-KB9-infected Ch Rh exhibiting different outcomes in contrast to in Ind Rh. Generally,the viral load values and the maintenance of CD4~+ T cells were associated with the humoral immune responses.Otherwise,the viral genetic distances (divergence,diversity) were larger in animals(M419,M425) in which the CD4~+ T cells were profound depleted.Ch Rh model employing SHIV-KB9 displayed a relative slower progression to AIDS compared with Ind Rh,which may more accurately reflect the potential of candidate vaccines in humans.Interesting, SHIV-CN97001 and SHIV-KB9 infection in Chinese-origin Rhesus Macaques could induce heterologous and homologous immune protective response to SHIV-KB9 superinfection.So it is not suitable for SHIV-KB9 superinfection in Chinese monkeys systemicly infected with SHIVs.
To contain the pandemic of HIV/AIDS in china,plasmids containing nef,gag, pol,gp140 and replication competent Tiantan vaccinia(rTV) containing gag,pol and gp140 from B'/C recombinant HIV-1 CN54,the predominant prevalent strain in China,were constructed as candidate AIDS vaccines.To evaluate the immunogenicity and protective effect against homologous SHIV-CN97001 and heterologous SHIV-KB9 challenge,12 Chinese-origin Rhesus Macaques were immunized and challenged,rTV-only vaccination was compared with a DNA prime/rTV boost strategy.Animals were followed prospectively for immune parameters and viral RNA loads.HIV-specific antibody titers and CTLs responses were determined with ELISA and ELISPOT based assay respectively.Neutralizing antibody titers were measured using a viral infectivity assay of TZM-bl cells.Compared to the DNA/rTV vaccine, the rTV-only vaccine raised less than 1/10 the number of vaccine-specific T cells,but comparative titers of binding antibody and neutralizing antibody.Otherwise,the candidate vaccines were able to induce strong memory responses in all the vaccinated animals nearly 9 months after the last immunization.After homologous SHIV-CN97001 challenge,the rTV-only-vaccinated animals had achieved better control of the infection.4 of 4 animals in rTV group were completely protected. However,only 1 of 3 animals in DNA prime/rTV boost group(M7) was complete protected,the other two animals were partially protected.After 10 months,we selected two animals which completely protected against SHIV-CN97001 to be rechallenged with heterologous SHIV-KB9,only one for each group.One monkey (M7) in DNA prime/ rTV boost group was also completely protected against SHIV-KB9 rechallenge,which was comfirmed by blood passage analysis,another one (M2) in rTV-only group was partially protected with declined peak and setpoint viral load.It was indicated that the rapid responses having neutralizing activity might contributed to the clearance of the homologous SHIV-CN97001 challenge virus and the IFN-γsecreting T cell immune response had correlation to protection from heterologous SHIV-KB9 rechallenge.
DNA-replication competent Tiantan vaccinia combined vaccine could provide the potent,persistent immunity necessary to protect against homologous and heterologous SHIV.This study provides a foundation for evaluation of these candidate vaccines in human body.
包含中国HIV-1 CRF07 BC主要流行株基因CCR5嗜性的致病性SHIV/中国恒河猴艾滋病模型在基于中国HIV-1主要流行株设计的艾滋病疫苗免疫保护效果评价中可以发挥非常重要的作用。SHIV-XJ02170感染性分子克隆是以B亚型强毒株SHIV-KB9基因为框架重组入中国CRF07 BC亚型HIV-1主要流行株env基因构建而成,本研究将SHIV-XJ02170连同Ruth M Ruprecht教授惠赠的另一株包含CRF07 BC亚型HIV-1 env的SHIV-CN97001分别在中国恒河猴体内快速传代。经过近4年的连续猴体传代和长期适应后,通过病毒载量和外周血CD4~+T淋巴细胞计数分析未发现致病性强毒株的出现。不过,两株SHIV病毒在猴体传代过程中表现出病毒毒力增强的特点。其中,SHIV-CN97001在前3代中病毒复制能力持续升高。更为重要的是,SHIV-XJ02170传代中的两只动物表现出潜伏期稳定的低水平病毒血症过程。
为了分析SHIV-CN97001和SHIV-XJ02170传代过程中序列变异特点,扩增各代动物急性期病毒载量峰值时间点病毒RNA Gp120克隆序列并分析病毒准种之间的基因离散率和遗传多样性。SHIV-CN97001传代过程中基因距离表现出先升后降的趋势,其中第三代动物中基因离散率和遗传多样性最显著。SHIV-XJ02170传代中的408动物体内病毒相对于原始序列基因离散率在适应过程中持续上升。分析发现各代动物基因离散率和病毒复制能力之间存在相关性。基因多态性分析发现两株SHIV病毒Gp120 V3区在传代过程中均最为保守。基于V3区关键氨基酸位点分析发现所有RNA克隆序列均利用CCR5作为辅助受体,传代过程中未发生改变。总体而言,SHIV-CN97001和SHIV-XJ02170传代过程中Gp120基因距离未出现明显上升,并且每代动物传代早期出现典型的“瓶颈效应”。按照Mullins教授提出的HIV-1感染后致病过程不同阶段基因距离变化理论分析,SHIV-XJ02170在第二代动物408体内目前已经处于感染的后期阶段。病毒准种基因变异分析可以部分解释两株SHIV病毒在中国恒河猴体内传代过程中未出现致病性强毒株的原因。
为建立致病性SHIV-KB9/中国恒河猴艾滋病疫苗评价模型并比较SHIV-KB9在中国恒河猴和印度恒河猴体内致病模式的差异。7只Mamu-A~*01阴性的中国恒河猴静脉途径接种1-1000 MID_(50)剂量的SHIV-KB9并监测病毒载量、CD4/CD8比值、SHIV特异性抗体滴度以及病毒序列变异。在中国恒河猴中,SHIV-KB9表现出和文献报道的印度恒河猴中相同的三种致病模式。然而,SHIV-KB9在两亚种动物中的主要致病模式是不同的。另外,SHIV-KB9感染中国恒河猴后三种致病模式中病毒血症的特点与印度恒河猴是不同的。对比发现,病毒载量和CD4~+T细胞的维持能力与体液免疫反应相关。值得注意的是,在CD4~+T细胞显著下降的动物体内SHIV-KB9病毒准种的基因离散率和遗传多样性明显升高。SHIV-KB9在中国恒河猴体内表现出相对印度恒河猴致病过程进展更加缓慢的特点,这一特点更加接近HIV-1在人体的致病特点并更适合做为艾滋病疫苗的评价模型。另外,SHIV-CN97001和SHIV-KB9感染中国恒河猴后可以诱导针对SHIV-KB9的异源性和同源性免疫保护反应。因此,SHIV病毒成功感染中国恒河猴后继续进行SHIV-KB9二次攻毒试验在中国恒河猴艾滋病疫苗免疫保护效果评价中是不适合的。
为了控制艾滋病在中国的流行,本研究团队研制了包含中国CRF07_BC亚型主要流行毒株HIV-1 CN54 gag,pol,nef以及gp140基因的DNA疫苗和复制性天坛株重组痘苗病毒载体疫苗(rTV)。为了评价本疫苗的免疫源性和攻毒保护效果并分析DNA疫苗的初免效果,采用rTV单免和DNA/rTV联合免疫两种策略免疫12只中国恒河猴,并选用同源性SHIV-CN97001和异源性SHIV-KB9二次攻毒的方式分析疫苗的免疫保护效果。免疫和攻毒后,监测细胞和体液免疫反应以及病毒载量的变化。HIV特异性结合抗体滴度和IFN-γ分泌性T细胞免疫反应分别采用ELISA和ELISPOT方法分析,中和抗体滴度通过测定SHIV-KB9在TZM-bl细胞的感染能力进行分析。相比rTV单免组,DNA/rTV联合免疫组动物疫苗免疫后可以诱导10倍以上水平的IFN-γ分泌性T细胞免疫反应,但诱导的结合抗体和中和抗体滴度水平没有明显差异。两种免疫策略均可以在最后一次痘苗免疫9个月后诱导出很强的记忆性免疫反应。
同源性SHIV-CN97001病毒攻击后,rTV单免组全部4只动物均获得完全性保护的效果。然而,DNA/rTV联合免疫组3只动物中仅有1只动物获得完全性保护效果,其它2只动物获得部分性保护效果。10个月之后,两组中各挑选1只针对SHIV-CN97001完全性保护的动物进行异源性SHIV-KB9的二次病毒攻击。联合免疫组中M7动物通过病毒载量和血液传代分析依然保持完全性保护的效果,而rTV单免组M2动物仅获得部分性保护的效果,表现为急性期病毒载量峰值水平下降以及潜伏期病毒载量下降至低于最低检测限水平。分析发现在同源性SHIV-CN97001免疫保护方面中和抗体可能发挥了关键性作用,而在异源性SHIV-KB9免疫保护方面IFN-γ分泌性T细胞免疫反应和免疫保护密切相关。
DNA-复制性重组痘苗病毒艾滋病疫苗免疫中国恒河猴后提供有效且持续性的免疫反应,可以有效的保护动物抵抗同源性和异源性SHIV病毒的攻击。本研究可以对艾滋病疫苗的临床试验提供有效的参考数据。
Human immunodeficiency virus(HIV) infection and AIDS continue to be a growing problem for the world's population.The need to develop a safe and efficacious vaccine against HIV is more pressing than ever.
A pathogenic R5 simian-human immunodeficiency virus(SHIV) encoding genes of the predominant prevalent HIV-1 B'/C Recombinant(CRF07_BC) strain in China was highly desirable to study the role of HIV-1 envelopes in transmission and pathogenesis as well as to evaluate candidate AIDS vaccines in nonhuman primates. To this end,SHIV-XJ02170 and SHIV-CN97001 which also carrying CRF07_BC env, were adapted by serial passage in thirteen Chinese-origin Rhesus Macaques,separately. Up to now,there were no pathogenic viral strain obtained during in vivo passage by viral load and CD4/CD8 ratio analysis.But,it was revealed that the infectivity property of the two SHIVs enhanced during in vivo passage.The viral RNA load of third passage was highest during SHIV-CN97001 passage and two animals infected SHIV-XJ02170 had inclined setpoint viral load.
To identify variation in the gpl20 region of SHIV-CN97001 and SHIV-XJ02170 during passage,the fragments of gpl20 gene were amplified by RT-PCR from the plasma of infected animals at the peak viral load time point and the gene distances (divergence,diversity) were calculated using DISTANCE.The analysis revealed that the genetic distances of SHIV-CN97001 in the third passage animals were the highest and the gene divergence from founder strain in M408 serially inclined during SHIV-XJ02170 in vivo adaption.It had a relationship between viral divergence from the founder strain and viral replication ability.In the two SHIV constructs,the nucleic acid sequence of the V3 region was highly conservative and all the RNA clones were predicted to be using CCR5 co-receptor on the basis of the critical amino acids within V3 loop.These results showed that there was no significant increase in the genetic distance during SHIV-CN97001 and SHIV-XJ02170 passage,and the two SHIV gp120 gene evolved toward ancestral states upon transmission to a new host.But,the SHIV-XJ02170 virus in one of second passage animals(408) maybe has involved the late infection phase according to gene distance analysis.This could partly explain why there has no pathogenic viral strain obtained during in vivo passage.
To develop a SHIV-KB9/Chinese-origin rhesus macaques(Ch Rh) model for vaccine research and to compare the pathogenesis of SHIV-KB9 in Ch Rh with published reports from Indian-origin rhesus macaques(Ind Rh).Seven mamu-A*01 negative Ch Rh were inoculated intravenously with 1-1000 MID_(50) of SHIV-KB9.The monkeys were monitored by measured viral load,CD4,CD8,SHIV-specific antibody and virus genetic variation.In Ch Rh,SHIV-KB9 displayed three identical disease progression patterns,compared to what observed in Ind Rh.However,the primary pattern was not same for the two subspecies.The level of plasma viremia differed in SHIV-KB9-infected Ch Rh exhibiting different outcomes in contrast to in Ind Rh. Generally,the viral load values and the maintenance of CD4~+ T cells were associated with the humoral immune responses.Otherwise,the viral genetic distances (divergence,diversity) were larger in animals(M419,M425) in which the CD4~+ T cells were profound depleted.Ch Rh model employing SHIV-KB9 displayed a relative slower progression to AIDS compared with Ind Rh,which may more accurately reflect the potential of candidate vaccines in humans.Interesting, SHIV-CN97001 and SHIV-KB9 infection in Chinese-origin Rhesus Macaques could induce heterologous and homologous immune protective response to SHIV-KB9 superinfection.So it is not suitable for SHIV-KB9 superinfection in Chinese monkeys systemicly infected with SHIVs.
To contain the pandemic of HIV/AIDS in china,plasmids containing nef,gag, pol,gp140 and replication competent Tiantan vaccinia(rTV) containing gag,pol and gp140 from B'/C recombinant HIV-1 CN54,the predominant prevalent strain in China,were constructed as candidate AIDS vaccines.To evaluate the immunogenicity and protective effect against homologous SHIV-CN97001 and heterologous SHIV-KB9 challenge,12 Chinese-origin Rhesus Macaques were immunized and challenged,rTV-only vaccination was compared with a DNA prime/rTV boost strategy.Animals were followed prospectively for immune parameters and viral RNA loads.HIV-specific antibody titers and CTLs responses were determined with ELISA and ELISPOT based assay respectively.Neutralizing antibody titers were measured using a viral infectivity assay of TZM-bl cells.Compared to the DNA/rTV vaccine, the rTV-only vaccine raised less than 1/10 the number of vaccine-specific T cells,but comparative titers of binding antibody and neutralizing antibody.Otherwise,the candidate vaccines were able to induce strong memory responses in all the vaccinated animals nearly 9 months after the last immunization.After homologous SHIV-CN97001 challenge,the rTV-only-vaccinated animals had achieved better control of the infection.4 of 4 animals in rTV group were completely protected. However,only 1 of 3 animals in DNA prime/rTV boost group(M7) was complete protected,the other two animals were partially protected.After 10 months,we selected two animals which completely protected against SHIV-CN97001 to be rechallenged with heterologous SHIV-KB9,only one for each group.One monkey (M7) in DNA prime/ rTV boost group was also completely protected against SHIV-KB9 rechallenge,which was comfirmed by blood passage analysis,another one (M2) in rTV-only group was partially protected with declined peak and setpoint viral load.It was indicated that the rapid responses having neutralizing activity might contributed to the clearance of the homologous SHIV-CN97001 challenge virus and the IFN-γsecreting T cell immune response had correlation to protection from heterologous SHIV-KB9 rechallenge.
DNA-replication competent Tiantan vaccinia combined vaccine could provide the potent,persistent immunity necessary to protect against homologous and heterologous SHIV.This study provides a foundation for evaluation of these candidate vaccines in human body.
引文
[1]Wu Z,Sun X,Sullivan SG,Detels R.Public health,HW testing in China.Science(New York,NY 2006 Jun 9;312(5779):1475-6.
[2]Louvel S,Battegay M,Vernazza P,Bregenzer T,Klimkait T,Hamy F.Detection of drug-resistant HIV minorities in clinical specimens and therapy failure.HIV medicine 2008 Feb 17;9(3):133-41.
[3]Vazquez E.Side effect chart.An abbreviated at-a-glance guide to potential HW drug side effects.Posit Aware 2007 Jan-Feb;18(1):53-4.
[4]Zhang L,Zhu J,Rui B,Zhang Y,Zhang L,Yin L,et al.High HIV risk among Uigur minority ethnic drug users in northwestern China.Trop Med Int Health 2008 Mar 24.
[5]Mutundwa A.International partnerships in the fight against AIDS.AIDS analysis Afi'ica 1999Oct-Nov;10(3):15-6.
[6]Stump DS,VandeWoude S.Animal models for HIV AIDS:a comparative review.Comparative medicine 2007Feb;57(1):33-43.
[7]Haga T,Kuwata T,Ui M,Igarashi T,Miyazaki Y,Hayami M.A new approach to AIDS research and prevention:the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines.Microbiol Immunol 1998;42(4):245-51.
[8]McClure HM,Anderson DC,Ansari AA,Klumpp SA.The simian immunodeficiency virus infected macaque:a model for pediatric AIDS.Pathol Biol(Paris) 1992 Sep;40(7):694-700.
[9]Sato S,Johnson W.Antibody-mediated neutralization and simian immunodeficiency virus models of HIV/AIDS.Curr HIV Res 2007 Nov;5(6):594-607.
[10]Narayan SV,Mukherjee S,Jia F,Li Z,Wang C,Foresman L,et al.Characterization of a neutralization-escape variant of SHIVKU-1,a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.Virology 1999 Mar 30;256(1):54-63.
[11]Kumar A,Lifson J'D,Li Z,Jia F,Mukherjee S,Adany I,et al.Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus(SHIV(89.6)P).Virology 2001 Jan 5;279(1):241-56.
[12]Ui M,Kuwata T,Igarashi T,Ibuki K,Miyazaki Y,Kozyrev IL,et al.Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heteroiogous Env by vaccination with multiple gene-deleted SHIVs.Virology 1999 Dec 20;265(2):252-63.
[13]Shibata IL Sakai H,Kiyomasu T,Ishimoto A,Hayami M,Adachi A.Generation and charactefizaton of infectious chimeric clones between human immunodeficiency virus type 1 and simian immunodeficiency virus from an African green monkey.Journal of virology 1990 Dec;64(12):5861-8.
[14]Joag SV.Primate models of AIDS.Microbes and infection / Institut Pasteur 2000 Feb;2(2):223-9.
[15]Dunn CS,Beyer C,Kieny MP,Gloeckler L,Schmitt D,Gut JP,et al.High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env,rev,tat,and vpu genes from HIV-1 Lai.Virology 1996 Sep 15;223(2):351-61.
[16]Li JT,Halloran M,Lord CI,Watson A,Ranchalis J,Fung M,et al.Persistent infection of macaques with simian-human immunodeficiency viruses.Journal of virology 1995 Nov;69(11):7061-7.
[17]Ranjbar S,Jones S,Stott EJ,Almond N.The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates.AIDS research and human retroviruses 1997 Jun 10;13(9):797-800.
[18]Reimann KA,Li.IT,Veazey R,Halloran M,Park IW,Karlsson GB,et al.A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.Journal of virology 1996Oct;70(10):6922-8.
[19]Puren AJ.The HIV-1 epidemic in South Africa.Oral diseases 2002;8 Suppl 2:27-31.
[20]Cayabyab M,Rohne D,Pollakis G,Mische C,Messele T,Abebe A,et al.Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate.AIDS research and human retroviruses 2004 Jan;20(1):27-40.
[21]Chen Z,Huang Y,Zhao X,Skulsky E,Lin D,Ip J,et al.Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques(Macaca nemestrina).Journal of virology 2000 Jul;74(14):6501-10.
[22]Ndung'u T,Lu Y,Renjifo B,Touzjian N,Kushner N,Pena-Cruz V,et al.Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate:rhesus macaque model.Journal of virology 2001 Dec;75(23):11417-25.
[23]Balfe P,Shapiro S,Hsu M,Buckner C,Harouse JM,Cheng-Mayer C.Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques.Virology 2004 Jan 5;318(1):267-79.
[24]Song RJ,Chenine AL,Rasmussen RA,Ruprecht CR,Mirshahidi S,Grisson RD,et al.Molecularly cloned SHIV-1157ipd3N4:a highly replication-competent,mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.Journal of virology 2006 Sep;80(l 7):8729-38.
[25]Heeney JL.Primate models for AIDS vaccine development.AIDS(London,England)1996;10 Suppl A:S115-22.
[26]Karlsson GB,Halloran M,Li J,Park IW,Gomila R,Reimann KA,et al.Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.Journal of virology 1997 Jun;71(6):4218-25.
[27]Cohen J.AIDS research.Vaccine studies stymied by shortage of animals.Science(New York,NY 2000 Feb 11;287(5455):959-60.
[28]Kanthaswamy S,Smith DG Effects of geographic origin on captive Macaca mulatta mitochondrial DNA variation.Comparative medicine 2004 Apr;54(2):193-201.
[29]Lifson JD,Rossio JL,Piatak M,Jr.,Parks T,Li L,Riser R,et al.Role of CD8(+)lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.Journal of virology 2001 Nov;75(21):10187-99.
[30]Ling B,Veazey RS,Luckay A,Penedo C,Xu K,Lifson JD,et al.SlV(mac)pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans.AIDS(London,England)2002 Jul 26;16(11):1489-96.
[31]Kourtis AP,Ibegbu CC,Scinicariello F,Oh CY,McClure HM.SHIV-KB9 infection of rhesus monkeys does not always cause disease-contribution of host immune factors and thymic output.Virology 2002 Nov 10;303(1):47-57.
[32]Allen TM,Vogel TU,Fuller DH,Mothe BR,Steffen S,Boyson JE,et al.Induction of AIDS virus-specific CTL activity in fresh,unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.J Immunol 2000 May l;164(9):4968-78.
[33]Gherardi MM,Ramirez JC,Esteban M.Towards a new generation of vaccines:the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens.Histology and histopathology 2001 Apr;16(2):655-67.
[34]Letvin NL.Progress in the development of an HIV-1 vaccine.Science(New York,NY 1998 Jun 19;280(5371):1875-80.
[35]McShane H.Prime-boost immunization strategies for infectious diseases.Current opinion in molecular therapeutics 2002 Feb;4(1):23-7.
[36]Malkevitch NV,Robert-Guroff M.A call for replicating vector prime-protein boost strategies in HIV vaccine design.Expert review of vaccines 2004 Aug;3(4 Suppl):S105-17.
[37]Peng B,Wang LR,Gomez-Roman VR,Davis-Warren A,Montefiori DC,Kalyanaraman VS,et al.Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Journal of virology 2005 Aug;79(16):10200-9.
[38]Bonnet MC,Tartaglia J,Verdier F,Kourilsky P,Lindberg A,Klein M,et al.Recombinant viruses as a tool for therapeutic vaccination against human cancers.Immunology letters 2000 Sep 15;74(1):11-25.
[39]Hi ll AV,Reece W,Gothard P,Moorthy V,Roberts M,Flanagan K,et al.DNA-based vaccines for malaria:a heterologous prime-boost immunisation strategy.Developments in biologicals 2000;104:171-9.
[40]Amara RR,Villinger F,Staprans SI,Altaian JD,Montefiori DC,Kozyr NL,et al.Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara(MVA)and DNA/MVA vaccines.Journal of virology 2002 Aug;76(15):7625-31.
[41]Liu Q,Li J,Yang GB,Xing H,Dai JJ,Shao YM.[Establishment of a real-time RT-PCR to detect plasma viral load of simian/human immunodeficiency virus CN97001 during its in vivo passage in rhesus monkeys].Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi =Chinese journal of experimental and clinical virology 2007 Jun;21(2):174-6.
[42]Wu Y,Hong K,Chenine AL,Whitney JB,Xu W,Chen Q,et al.Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate.Journal of medical primatology 2005 Apr,34(2):101-7.
[43]Li J,Lord CI,Haseltine W,Letvin NL,Sodroski J.Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.J Acquir Immune Defic Syndr 1992;5(7):639-46.
[44]Reimann KA,Li JT,Voss G,Lekutis C,Tenner-Racz K,Racz P,et al.An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.Journal of virology 1996 May;70(5):3198-206.
[45]Hofmann-Lehmann R,Swenerton RK,Liska V,Leutenegger CM,Lutz H,McClure HM,et al.Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load:comparison of one-versus two-enzyme systems.AIDS research and human retroviruses 2000 Sep 1;16(13):1247-57.
[46]Barnett SW,Srivastava IK,Kan E,Zhou F,Goodsell A,Cristillo AD,et al.Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.Aids 2008 Jan 30;22(3):339-48.
[47]Chenine AL,Buckley KA,Li PL,Rasmussen RA,Ong H,Jiang S,et al.Schistosoma mansoni infection promotes SHIV clade C replication in rhesus macaques.Aids 2005 Nov 4;19(16):1793-7.
[48]Horiuchi R,Akahata W,Kuwata T,Enose Y,Ido E,Suzuki H,et al.DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles.Vaccine 2006 Apr24;24(17):3677-85.
[49]Barletta JM,Edelman DC,Constantine NT.Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen.Am J Clin Pathol 2004 Jul;122(1):20-7.
[50]Manfredi R,Borderi M,Re MC,Furlini G,Monari P,Spinosa Guzman SM,et al.A comparison of immunocomplex-dissociated serum HIV-1 p24 antigenemia and plasma HIV-1 viral load:assessment of 3,129 paired assays.New Microbiol 1999 Jul;22(3):269-75.
[51]Sutthent R,Gaudart N,Chokpaibulkit K,Tanliang N,Kanoksinsombath C,Chaisilwatana P.p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection.J Clin Microbiol 2003 Mar;41(3):1016-22.
[52]Giorgi JV,Lyles RH,Matud JL,Yamashita TE,Mellors JW,Hultin LE,et al.Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.J Acquir Immune Defic Syndr 2002 Apr l;29(4):346-55.
[53]Aschbacher R,Monari P,Loili S,Donzelli C,Colangeli V,Vignoli M,et al.Evaluation of three different commercial procedures for quantifying human immunodeficiency virus type-1 RNA levels.New Microbiol 1999 Jan;22(1):1-9.
[54]Coste J,Montes B,Reynes J,Peeters M,Segarra C,Vendrell JP,et al.Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma.Journal of medical virology 1996 Dec;50(4):293-302.
[55]Hodara V,Monticelli A,Pampuro S,Salomon H,Jauregui Rueda H,Libonatti O.HIV-1 viral load: comparative evaluation of three commercially available assays in Argentina.Acta Physiol Pharmacol Ther Latinoam 1998;48(2):107-13.
[56]Leutenegger CM,Higgins J,Matthews TB,Tarantal AF,Luciw PA,Pedersen NC,et al.Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA.AIDS research and human retroviruses 2001 Feb 10;17(3):243-51.
[57]Joag SV,Li Z,Foresman L,Stephens EB,Zhao L J,Adany I,et al.Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.Journal of virology 1996May;70(5):3189-97.
[58]Luciw PA,Pratt-Lowe E,Shaw KE,Levy JA,Cheng-Mayer C.Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses(SHIV).Proceedings of the National Academy of Sciences of the United States of America 1995 Aug 1;92(16):7490-4.
[59]Ten Haaft P,Verstrepen B,Uberla K,Rosenwirth B,Heeney J.A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian-human immunodeficiency virus-infected macaques.Journal of virology 1998 Dec;72(12):10281-5.
[60]Herbeck JT,Nickle DC,Learn GH,Gottlieb GS,Curlin ME,Heath L,et al.Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host.Journal of virology 2006Feb;80(4):1637-44.
[61]Liang H,Wei M,Chert Z,Xing H,Zhao QB,Feng Y,et al.[Sequence variation in the env V3-V4 region of HIV type 1 predominant subtype B and C strains circulating in China].Zhonghua shi yan he iin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology 2003 Jun;17(2):153-8.
[62]Nowak MA,Anderson RM,McLean AR,Wolfs TF,Goudsmit J,May RM.Antigenic diversity thresholds and the development of AIDS.Science(New York,NY 1991 Nov 15;254(5034):963-9.
[63]Harouse JM,Gettie A,Tan RC,Blanchard J,Cheng-Mayer C.Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.Science(New York,NY 1999 Apr 30;284(5415):816-9.
[64]Shankarappa R,Margolick JB,Gange S J,Rodrigo AG,Upchurch D,Farzadegan H,et al.Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type I infection.Journal of virology 1999 Dec;73(l 2):10489-502.
[65]Chackerian B,Rudensey LM,Overbaugh J.Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.Journal of virology 1997 Oct;71(10):7719-27.
[66]Bergstrom CT,McEihany P,Real LA.Transmission bottlenecks as determinants of virulence in rapidly evolving pathogens.Proceedings of the National Academy of Sciences of the United States of America 1999Apt 27;96(9):5095-100.
[67]Eigen M.On the nature of virus quasispecies.Trends in microbiology 1996 Jun;4(6):216-8.
[68]Meyerhans A,Cheynier R,Albert J,Seth M,Kwok S,Sninsky J,et al.Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.Cell 1989 Sep 8;58(5):901-10.
[69]Liu SL,Rodrigo AG,Shankarappa R,Learn GH,Hsu L,Davidov O,et al.HIV quasispecies and resampling.Science(New York,NY 1996 Jul 26;273(5274):415-6.
[70]Manrubia SC,Escarmis C,Domingo E,Lazaro E.High mutation rates,bottlenecks,and robustness of RNA viral quasispecies.Gene 2005 Mar 14;347(2):273-82.
[71]Learn GH,Muthui D,Brodie SJ,Zhu T,Diem K,Mullins JI,et al.Virus population homogenization following acute human immunodeficiency virus type 1 infection.Journal of virology 2002Dec;76(23):11953-9.
[72]Mellors JW,Munoz A,Giorgi JV,Margolick JB,Tassoni C J,Gupta P,et al.Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection.Annals of internal medicine 1997 Jun 15;126(12):946-54.
[73]Mellors JW,Rinaldo CR,Jr.,Gupta P,White RM,Todd JA,Kingsley LA.Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.Science(New York,NY 1996 May 24;272(5265):1167-70.
[74]Shearer WT,Quinn TC,LaRussa P,Lew JF,Mofenson L,Almy S,et al.Viral load and disease progression in infants infected with human immunodeficiency virus type 1.Women and Infants Transmission Study Group.The New England journal of medicine 1997 May 8;336(19):1337-42.
[75]Rasmussen RA,Ong H,Song R,Chenine AL,Ayash-Rashkovsky M,Hu SL,et al.Efficacy of a multigenic protein vaccine containing multimeric HIV gpl60 against heterologous SHIV clade C challenges.AIDS (London,England) 2007 Sep 12;21(14):1841-8.
[76]Ganeshan S,Dickover RE,Korber BT,Bryson Y J,Wolinsky SM.Human immunodeficiency virus type 1genetic evolution in children with different rates of development of disease.Journal of virology 1997Jan;71(1):663-77.
[77]Wolinsky SM,Korber BT,Neumarm AU,Daniels M,Kunstman K J,Whet,ell AJ,et al.Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.Science(New York,NY 1996Apr 26;272(5261):537-42.
[78]Mani I,Gilbert P,Sankale JL,Eisen G,Mboup S,Kanki PJ.Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection.Journal of virology 2002Nov;76(21):10745-55.
[79]Choisy M,Woelk CH,Gucgan JF,Robertson DL.Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes.Journal of virology 2004 Feb;78(4):1962-70.
[80]Derdeyn CA,Decker JM,Bibollet-Ruche F,Mokili JL,Muldoon M,Denham SA,et al.Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.Science(New York,NY 2004 Mar 26;303(5666):2019-22.
[81]Chen W,Helenius J,Braakman I,Helenius A.Cotranslational folding and calnexin binding during glycoprotein synthesis.Proceedings of the National Academy of Sciences of the United States of America 1995 Jul 3;92(14):6229-33.
[82]Wei X,Decker JM,Wang S,Hui H,Kappes JC,Wu X,et al.Antibody neutralization and escape by HIV-1.Nature 2003 Mar 20;422(6929):307-12.
[83]Hofinann-Lehmann R,Vlasak J,Chenine AL,Li PL,Baba TW,Montefiori DC,et al.Molecular evolution of human immunodeficiency virus env in humans and monkeys:similar patterns occur during natural disease progression or rapid virus passage.Journal of virology 2002 May;76(10):5278-84.
[84]Oelrichs RB,Shrestha IL,Anderson DA,Deacon NJ.The explosive human immunodeficiency virus type 1epidemic among injecting drug users of Kathmandu,Nepal,is caused by a subtype C virus of restricted genetic diversity.Journal of virology 2000 Feb;74(3):1149-57.
[85]Zhang H,Hoffmann F,He.I,He X,Kankasa C,Ruprecht R,et al.Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.Retrovirology 2005;2:67.
[86]Reimann KA,Watson A,Dailey PJ,Lin W,Lord CI,Steenbeke TD,et al.Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.Virology 1999 Mar 30;256(1):15-21.
[87]Ellenberger D,Otten RA,Li B,Aidoo M,Rodriguez IV,Sariol CA,et al.HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.Virology 2006Aug 15;352(1):216-25.
[88]Kyes RC,Iones-Engel L,Chalise MK,Engel G,Heidrich J,Grant R,et al.Genetic characterization of rhesus macaques(Macaca mulatta) in Nepal.American.journal of primatology 2006 May;68(5):445-55.
[89]Trichel AM,Rajakumar PA,Murphey-Corb M.Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque.Journal of medical primatology 2002 Aug;31(4-5):171-8.
[90]Pal R,Venzon D,Letvin NL,Santra S,Montefiori DC,Miller NR,et aL ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class 1(A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.Journal of virology 2002 Jan;76(1):292-302.
[91]Muhl T,Krawczak M,Ten Haafi P,Hunsmann G,Sauermann U.MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys.J Immunol 2002 Sep 15;169(6):3438-46.
[92]Vogel T,Norley S,Beer B,Kurth R.Rapid screening for Mamu-Al-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay.Immunology 1995 Mar;84(3):482-7.
[93]Lafont BA,Buckler-White A,Plishka R,Buckler C,Martin MA.Pig-tailed macaques(Macaca nemestrina)possess six MHC-E families that are conserved among macaque species:implication for their binding to natural killer receptor variants.Immunogenetics 2004 Jun;56(3):142-54.
[94]Karlsson GB,Halloran M,Schenten D,Lee J,Racz P,Tenner-Racz K,et al.The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques.The Journal of experimental medicine 1998 Sop 21;188(6):1159-71.
[95]Ruprecht RM,Baba TW,Rasmussen R,Hu Y,Sharma PL.Murine and simian retrovirus models:the threshold hypothesis.AIDS(London,England) 1996;10 Suppl A:S33-40.
[96]Kaneyasu K,Kita M,Ohkura S,Yamamoto T,Ibuki K,Enose Y,et al.Protective efficacy of nonpathogenic nef-deleted SHIV vaccination combined with recombinant IFN-gamma administration against a pathogenic SHIV challenge in rhesus monkeys.Microbiology and immunology 2005;49(12):1083-94.
[97]Geleziunas R,Bout S,Wainberg MA.Cell surface down-modulation of CD4 after infection by HIV-1.Faseb J 1994 Jun;8(9):593-600.
[98]Gottlieb GS,Nickle DC,Jonson MA,Wong KG,Kaslow RA,Shepherd JC,et al.HIV type 1 superinfecfion with a dual-tropic virus and rapid progression to AIDS:a case report.Clin Infect Dis 2007 Aug 15;45(4):501-9.
[99]Hu SL,Travis BM,Stallard V,Abrams K,Misher L,Moran P,et al.Immune responses to SIVnme envelope glycoproteins protect macaques from homologous SIV infection.AIDS research and human retrovirnses 1992Aug;8(8):1489-94.
[100]Polacino PS,Stallard V,Klaniecki JE,Pennathur S,Montefiori DC,Langlois AJ,et al.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVnme in protection against homologous cloned and uncloned virus challenge in Macaques.Journal of virology 1999Oct;73(10):8201-15.
[101]Estcourt M J,Ramsay A J,Brooks A,Thomson SA,Medveckzy C J,Ramshaw IA.Prime-boost immunization generates a high frequency,high-avidity CDS(+) cytotoxic T lymphocyte population.International immunology 2002 Jan;14(I ):31-7.
[102]Schneider J,Gilbert SC,Hannah CM,Degano P,Prienr E,Sheu EG,et al.Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.Immunological reviews 1999 Aug;170:29-38.
[103]Amara RR,Smith JM,Staprans SI,Montefiori DC,Villinger F,Altman JD,et al.Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.Journal of virology 2002 Jun;76(12):6138-46.
[104]Amara RR,Villinger F,Altrnan JD,Lydy SL,O'Neil SP,Staprans SI,et al.Control ofa mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.Science(New York,NY 2001 Apr 6;292(5514):69-74.
[105]Barouch DH,Kunstman J,Glowczwskie J,Kunstman KJ,Egan MA,Peyerl FW,et al.Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys.Journal of virology 2003 Jul;77(13):7367-75.
[106]Doria-Rose NA,Ohlen C,Polacino P,Pierce CC,Hensel MT,Kuller L,et al.Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.Journal of virology 2003 Nov;77(21):11563-77.
[107]Fanales-Belasio E,Cafaro A,Cara A,Negri DR,Fiorelli V,Butto S,et al.HIV-1 Tat-based vaccines:from basic science to clinical trials.DNA and cell biology 2002 Sep;21(9):599-610.
[108]Shiver JW,Fu TM,Chen L,Casimiro DR,Davies ME,Evans RK,et al.Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.Nature 2002 Jan 17;415(6869):331-5.
[109]Shiver JW,Perry HC,Davies ME,Freed DC,Liu MA.Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.Annals of the New York Academy of Sciences 1995 Nov 27;772:198-208.
[110]Graham BS.Clinical trials of HIV vaccines.Annual review of medicine 2002;53:207-21.
[111]Gomez-Roman VR,Patterson LJ,Venzon D,Liewehr D,Aldrich K,Florese R,et al.Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.J Immuno12005 Feb 15;174(4):2185-9.
[112]Smith SM,Holland B,Russo C,Dailey PJ,Marx PA,Connor RI.Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV:predictive value for disease progression.AIDS research and human retroviruses 1999 Dec 10;15(18):1691-701.
[113]Cohen J.AIDS research.Promising AIDS vaccine's failure leaves field reeling.Science(New York,NY 2007 Oct 5;318(5847):28-9.
[114]Fontencau JF,Larsson M,Bhardwaj N.Interactions between dead cells and dendritic ceils in the induction of antiviral CTL responses.Current opinion in immunology 2002 Aug;14(4):471-7.
[115]Vogcls R,Zuijdgccst D,van Rijnsocvcr R,Hartkoorn E,Damen I,dc Bcthunc MP,et al.Replication-deficient human adenovirus type 35 vectors for gcnc transfer and vaccination:efficient human cell infection and bypass of preexisting adenovirus immunity.Journal of virology 2003 Aug;77(15):8263-71.
[116]TruckenmiIler ME,Norbury CC.Viral vectors for inducing CD8+ T cell responses.Expert opinion on biological therapy 2004 Jun;4(6):861-8.
[117]Wang B,Norbury CC,Greenwood R,Bermink JR,Ycwdcll JW,Frelingcr JA.Multiple paths for activation of naive CD8+ T ceils:CD4-independent help.J Immunol 2001 Aug 1;167(3):1283-9.
[118]Santra S,Barouch DH,Korioth-Schmitz B,Lord CI,Krivulka GR,Yu F,ctal.Recombinant poxvirus boosting of DNA-primcd rhesus monkeys augments peak but not memory T lymphocyte responses.Proceedings of the National Academy of Sciences of the United States of America 2004 Jul 27;101(30):11088-93.
[119]Stamatatos L,Davis D.New insights into protective humoral responses and HIV vaccines.Aids 2001;15Suppl 5:S105-15.
[120]Cao H,Kanki P,Sankale JL,Dieng-Sarr A,Mazzara GP,Kalams SA,ctal.Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades:implications for vaccine development.Journal of virology 1997 Nov;71(11):8615-23.
[121]McAdam S,Kaleebu P,Krausa P,Goulder P,French N,Collin B,eta!.Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection.Aids 1998 Apr 16;12(6):571-9.
[122]Nakamura Y,Kameoka M,Tobiume M,Kaya M,Ohki K,Yamada T,et al.A chain section containing epitopes for cytotoxic T,B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein.Vaccine 1997 Apt;15(5):489-96.
[123]Nishimura Y,Igarashi T,Haigwood NL,Sadjadpour IL Donau OK,Buckler C,et al.Transfer of neutralizing IgG to macaques 6 h but not 24 h aRer SHIV infection confers sterilizing protection:implications for HIV-1vaccine development.Proceedings of the National Academy of Sciences of the United States of America 2003 Dec 9;100(25):15131-6.
[124]Kaech SM,Ahmed R.Memory CD8+ T cell differentiation:initial antigen encounter triggers a developmental program in naive cells.Nature immunology 2001 May;2(5):415-22.
[125]Feinberg MB,Moore JP.AIDS vaccine models:challenging challenge viruses.Nature medicine 2002Mar;8(3):207-10.
[126]Barouch DH,Santra S,Schmitz JE,Kuroda M J,Fu TM,Wagner W,et al.Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.Science(New York,NY 2000Oct 20;290(5491):486-92.
[127]Earl PL,Wyatt LS,Montefiori DC,Bilska M,Woodward R,Markham PD,et al.Comparison of vaccine strategies using recombinant cnv-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.Virology 2002 Mar 15;294(2):270-81.
[1]McCormick-Davis C,Zhao LJ,Mukherjcc S,et al.Chronology of genetic changes in the vpu,env,and Ncf genes of chimeric simian-human immunodcficiency virus(strain HXB2) during acquisition of virulence for pig-tailed macaques.Virology.1998 Sep 1;248(2):275-83.
[2]Shibata R,Sakai H,Kiyomasu T,ctal.Gcncration and characterization of infectious chimeric clones between human immunodcficiency virus type 1 and simian immunodeficiency virus from an Aft-lean green monkey.J Virol.1990 Dcc;64(12):5861-68.
[3]Kuwata T,Takcmura T,Takchisa J,ctal.Infection of macaques with chimeric simian and human immunodcficicncy viruses containing Env from subtype F.Arch Virol.2002Jun;147(6):1121-32.
[4]Himathongkhana S,Douglas GC,Fang A,ct al.Species tropism of chimeric SHIV clones containing HIV-1 subtypc-A and subtypc-E envelope genes.Virology.2002 Jul 5;298(2):189-99.
[5]Shibata R,Kawamura M,Sakai H,ct al.Generation of a chimeric human and simian immunodeficiency virus infectious to monkcy peripheral blood mononuclcar cells.J Virol.1991Jui;65(7):3514-20.
[6]Luciw PA,Pratt-Lowc E,Shaw KE,Persistent infection of rhesus macaques with T-cell-line-tropic and macrophagc-tropic clones of simian/human immunodeficicncy viruses (SHIV).Proc Natl Acad Sci U S A.1995 Aug 1;92(16):7490-4.
[7]Li Jr,Halloran M,Lord CI,et al.Persistent infection of macaques with simian-human immunodcficicncy viruses.J Virol.1995 Nov;69(11):7061-7
[8]Joag SV,Li Z,Foresman L,et al.Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.J Virol.1996 May;70(5):3189-97.
[9]Durra CS,Beyer C,Kieny MP,et al.High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env,rev,tat,and vpu genes from HIV-1 Lai.Virology.1996 Sep 15;223(2):351-61
[10]Raghavan R,Stephens EB,Joag SV,et al.Neuropathogenesis of chimeric simian/human immunodeficiency virus infection in pig-tailed and rhesus macaques.Brain Pathol.1997Jul;7(3):851-61
[11]Reimann KA,Li JT,Veazey R,et al.A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.J Virol.1996 Oct;70(10):6922-8
[12]Reimann KA,Li JT,Voss G,et al.An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacitiy to a chimeric simian/human immunodeficiency virus in rhesus monkeys.J Virol.1996 May;70(5):3198-206
[13]Ranjbar S,Jones S,Stott EJ,et al.The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates.AIDS Res Hum Retroviruses.1997 Jun 10;13(9):797-800.
[14]Bogers WM,Dubbes R,ten Haaft P,et al.Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta.Virology.1997 Sep 15;236(1):110-7
[15]Narayan SV,Mukherjee S,Jia F,et al.Characterization of a neutralization-escape variant of SHIVKU-1,a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.Virology.1999 Mar 30;256(1):54-63.
[16]Lin ZQ,Muhkerjee S,Sahni M,et al.Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS,neurological disease,and renal disease in rhesus macaques.Virology.1999 Aug 1;260(2):295-307
[17]Chen Z,Huang Y,Zhao X,et al.Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques(Macaca nemestrina).J Virol.2000 Jul;74(14):6501-10.
[18]Ndung'u T,Lu Y,Renjifo B,et al.Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate:rhesus macaque model.J Virol.2001 Dec;75(23):11417-25.
[19]Cayabyab M,Rohne D,Pollakis G,et al.Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate.AIDS Res Hum Retroviruses.2004 Jan;20(1):27-40.
[20]Wu Y,Hong K,Chenine AL,et al.Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate.J Med Primatol.2005 Apr;34(2):101-7
[21]Kaizu M,Sato H,Ami Y,et al.Infection of macaques with an R5-tropic SHIV bearing a chimeric envelope carrying subtype E V3 loop among subtype B framework.Arch Virol.2003 May;148(5):973-88.
[22]Ranjbar S,Bhattacharya U,Oram J,et al.Construction of infectious SIV/HIV-2 chimeras.AIDS.2000 Nov 10;14(16):2479-84.
[23]Balzarini J,Weeger M,Camarasa MJ,et al.Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1(HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.Biochem Biophys Res Commun.1995 Jun 26;211(3):850-6
[24]Uberla K,Stahl-Hennig C,Bottiger D,et al.Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.Proc Natl Acad Sci U S A.1995 Aug 29;92(18):8210-4
[25]Akiyama H,Ido E,Akahata W,et al.Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type l.J Gen Virol.2003 Jul;84(Pt 7):1663-9
[26]Ambrose Z,Boltz V,Palmer S,et al.In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus(HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.J Virol.2004 Dec;78(24):13553-61.
[27]Kozyrev IL,Miura T,Takemura T,et al.Co-expression of interleukin-5 influences replication of simian/human immunodeficiency viruses in vivo.J Gen Virol.2002 May;83(Pt 5):1183-8.
[28]Kozyrev IL,Miura T,Haga T,et al.Construction of SIV/HIV-I chimeric viruses having the IL-5gene and determination of their ability to replicate and produce IL-5.Arch Virol.2001;146(6):1051-62
[29]Haga T,Shimizu Y,Okoba M,et al.Construction and in vitro properties of chimeric simian and human immunodeficiency virus with the human TNF-alpha gene.Microbiol Immunol.2002;46(12):849-55.
[30]Iida T,Kuwata T,Ui M,et al.Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma.Arch Virol.2004 Apr;149(4):743-57.Epub 2003 Dec 8.
[31]Haga T,Okoba M,Yamazaki N,et al.Characterization ofvpr vector constructed from chimeric simian and human immunodeficiency virus.J Vet Med Sci.2003 May;65(5):633-6.
[32]Hout DR,Gomez ML,Pacyniak E,et al.Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus(SHIV(KU1bMC33)) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques.Virology.2005 Sep 28
[33]Shimizu Y,Okoba M,Yamazald N,et al.Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene.Microbes Infect.2005
[34]Shimizu Y,Miyazaki Y,Ibuki K,et al.Induction of immune response in macaque monkeys infected with simian-human immunodeficiency virus having the TNF-alpha gene at an early stage of infection.Virology.2005 Sep 15
[35]Bertsch C,Cluet D,Beyer C,et al.Properties of a chimeric simian-human immunodeficiency virus expressing an hybrid HIV-1 Nef/SIVmac Nef protein.Arch Virol.2002,147(10):1963-75.
[36]Singh DK,McCormick C,Pacyniak E,et al.Pathogenic and nef-interrupted simian-human immunodeficiency viruses traffic to the macaque CNS and cause astrocytosis early after inoculation.Virology.2002 Apt 25;296(1):39-51.
[37]Buch S,Pinson D,King CL,et al.Inhibitory and enhancing effects of IFN-r and IL-4 on SHIV KU replication in rhesus macaque rnacrophages:correlation between TH2 cytokines and productive infection in tissue macrophages during late-stage infection.
[38]Igarashi T,Donau OK,Imamichi H,et al.Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4,not CCR5,for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages.J Virol.2003 Dec;77(24):13042-52.
[39]Lu Y,Brosio P,Lafaile M,et al.Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques.J Virol.1996 May;70(5):3045-50
[40]Joag SV,Li Z,Foresman L,et al.Chimeric simian/human immunodeficiency virus that causes progressive loss ofCD4+ T cells and AIDS in pig-tailed macaques.J Virol.1996,70(5):3189-97.
[41]Stephens EB,Mukherjee S,Sahni M,et al.A cell-free stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed macaques has a limited number of amino acid substitutions in both SIVmac and HIV-1 regions of the genome and has offered cytotropism.Virology.1997 May 12;231(2):313-21.
[42]Cayabyab M,Karlsson GB,Etemad-Moghadam BA,et al.Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus(SHIV-HXBc2).J Virol.1999 Feb;73(2):976-84.
[43]Song B,Cayabyab M,Phan N,et al.Neutralization sensitivity of a simian-human immunodeficiency virus(SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.Virology.2004 Apr 25;322(1):168-81.
[44]Karlsson GB,Halloran M,Li J,et al.Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.J Virol.1997 Jun;71(6):4218-25
[45]Song R J,Chenine A L,Rasmussen R A,et al.Molecularly Cloned SHIV-1157ipd3N4:a Highly Replication-Competent,Mucosally Transmissible R5 Simian-Human Immunodeficiency Virus Encoding HIV Clade C env.J Virol.2006 Sep;80(17):8729-38
[46]Balfe P,Shapiro S,Hsu M,et al.Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques
[47]Matano T,Shibata R,Siemon C,et al.Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques.J Virol.1998 Jan;72(1):164-9
[48]Seaman MS,Santra S,Newberg MH,et al.Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A~*01-associated control of s/m/an/human immunodeficiency virus 89.6P replication in rhesus monkeys.J Virol.2005 Apr;79(8):4580-8
[49]Zhang ZQ,Fu TM,Casimiro DR,et al.Mamu-A~*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection.J Virol.2002,76(24):12845-54.
[50]Ahmed RK,Makitalo B,Karlen K,et al.Spontaneous production of R.ANTES and antigenspecific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge.Clin Exp Immunol.2002 Jul;129(1):11-8.
[51]Wallace M,Waterman PM,Mitchen/L,et al.Lymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques.J Virol.1999,73(12):10236-44.
[52]Kumar R,Torres C,Yamamura Y,et al.Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus.J Virol.2004 Oct;78(20):11425-8.
[53]Kumar R,Perez-Casanova AE,Tirado G,et al.Increased viral replication in simian immunodeficiency virus/simian-HIV-infected macaques with self-administering model of chronic alcohol consumption.J Acquir Immune Defic Syndr.2005 Aug 1;39(4):386-90
[54]Suzuki H,Motohara M,Miyake A,et al.Intrathymic effect of acute pathogenic SHIV infection on T-lineage cells in newborn macaques.Microbiol Immunol.2005;49(7):667-79
[55]Sui Y,Li S,Pinson D,et al.Simian human immtmodeficiency virus-associated pneumonia correlates with increased expression of MCP-1,CXCL10,and viral RNA in the lungs of rhesus macaques.Am J Pathol.2005 Feb;166(2):355-65
[56]Endo Y,Igarashi T,Nishimura Y,et al.Short-and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.J Virol.2000 Aug;74(15):6935-45.
[57]ten Haaft P,Almond N,Biberfeld G,et al.Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection.J Med Primatol.2001 Aug;30(4):207-14.
[58]Ui M,Kuwata T,Igarashi T,et al.Protective immunity of gene-deleted SHIVs having an HIV-1Env against challenge infection with a gene-intact SHIV.J Med Primatol.1999,28(4-5):242-8
[59]Ui M,Kuwata T,Igarashi T,et al.Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.Virology.1999 Dec 20;265(2):252-63
[60]Kumar A,Lifson JD,Li Z,Jia F,et al.Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).Virology.2001 Jan 5;279(1):241-56.
[61]Rosenwirth B,Bogers WM,Nieuwenhuis IG,et al.An anti-HIV strategy combining chemotherapy and therapeutic vaccination.J Med Primatol.1999 Aug-Oct;28(4-5):195-205.
[62]Smith MS,Foresman L,Lopez G J,Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine]treatment on SHIV(KU2) infection of rhesus macaques.Virology.2000 Nov 25;277(2):306-15
[63]Veazey RS,Klasse PJ,Schader SM,et al.Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.Nature.2005 Nov 3;438(7064):99-102.
[64]Dhillon NK,Sui Y,Potula R,et al.Inhibition of pathogenic SHIV replication in macaques treated with antisense DNA of interleuldn-4.Blood.2005 Apt 15;105(8):3094-9.Epub 2004 Dec 23
[2]Louvel S,Battegay M,Vernazza P,Bregenzer T,Klimkait T,Hamy F.Detection of drug-resistant HIV minorities in clinical specimens and therapy failure.HIV medicine 2008 Feb 17;9(3):133-41.
[3]Vazquez E.Side effect chart.An abbreviated at-a-glance guide to potential HW drug side effects.Posit Aware 2007 Jan-Feb;18(1):53-4.
[4]Zhang L,Zhu J,Rui B,Zhang Y,Zhang L,Yin L,et al.High HIV risk among Uigur minority ethnic drug users in northwestern China.Trop Med Int Health 2008 Mar 24.
[5]Mutundwa A.International partnerships in the fight against AIDS.AIDS analysis Afi'ica 1999Oct-Nov;10(3):15-6.
[6]Stump DS,VandeWoude S.Animal models for HIV AIDS:a comparative review.Comparative medicine 2007Feb;57(1):33-43.
[7]Haga T,Kuwata T,Ui M,Igarashi T,Miyazaki Y,Hayami M.A new approach to AIDS research and prevention:the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines.Microbiol Immunol 1998;42(4):245-51.
[8]McClure HM,Anderson DC,Ansari AA,Klumpp SA.The simian immunodeficiency virus infected macaque:a model for pediatric AIDS.Pathol Biol(Paris) 1992 Sep;40(7):694-700.
[9]Sato S,Johnson W.Antibody-mediated neutralization and simian immunodeficiency virus models of HIV/AIDS.Curr HIV Res 2007 Nov;5(6):594-607.
[10]Narayan SV,Mukherjee S,Jia F,Li Z,Wang C,Foresman L,et al.Characterization of a neutralization-escape variant of SHIVKU-1,a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.Virology 1999 Mar 30;256(1):54-63.
[11]Kumar A,Lifson J'D,Li Z,Jia F,Mukherjee S,Adany I,et al.Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus(SHIV(89.6)P).Virology 2001 Jan 5;279(1):241-56.
[12]Ui M,Kuwata T,Igarashi T,Ibuki K,Miyazaki Y,Kozyrev IL,et al.Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heteroiogous Env by vaccination with multiple gene-deleted SHIVs.Virology 1999 Dec 20;265(2):252-63.
[13]Shibata IL Sakai H,Kiyomasu T,Ishimoto A,Hayami M,Adachi A.Generation and charactefizaton of infectious chimeric clones between human immunodeficiency virus type 1 and simian immunodeficiency virus from an African green monkey.Journal of virology 1990 Dec;64(12):5861-8.
[14]Joag SV.Primate models of AIDS.Microbes and infection / Institut Pasteur 2000 Feb;2(2):223-9.
[15]Dunn CS,Beyer C,Kieny MP,Gloeckler L,Schmitt D,Gut JP,et al.High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env,rev,tat,and vpu genes from HIV-1 Lai.Virology 1996 Sep 15;223(2):351-61.
[16]Li JT,Halloran M,Lord CI,Watson A,Ranchalis J,Fung M,et al.Persistent infection of macaques with simian-human immunodeficiency viruses.Journal of virology 1995 Nov;69(11):7061-7.
[17]Ranjbar S,Jones S,Stott EJ,Almond N.The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates.AIDS research and human retroviruses 1997 Jun 10;13(9):797-800.
[18]Reimann KA,Li.IT,Veazey R,Halloran M,Park IW,Karlsson GB,et al.A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.Journal of virology 1996Oct;70(10):6922-8.
[19]Puren AJ.The HIV-1 epidemic in South Africa.Oral diseases 2002;8 Suppl 2:27-31.
[20]Cayabyab M,Rohne D,Pollakis G,Mische C,Messele T,Abebe A,et al.Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate.AIDS research and human retroviruses 2004 Jan;20(1):27-40.
[21]Chen Z,Huang Y,Zhao X,Skulsky E,Lin D,Ip J,et al.Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques(Macaca nemestrina).Journal of virology 2000 Jul;74(14):6501-10.
[22]Ndung'u T,Lu Y,Renjifo B,Touzjian N,Kushner N,Pena-Cruz V,et al.Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate:rhesus macaque model.Journal of virology 2001 Dec;75(23):11417-25.
[23]Balfe P,Shapiro S,Hsu M,Buckner C,Harouse JM,Cheng-Mayer C.Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques.Virology 2004 Jan 5;318(1):267-79.
[24]Song RJ,Chenine AL,Rasmussen RA,Ruprecht CR,Mirshahidi S,Grisson RD,et al.Molecularly cloned SHIV-1157ipd3N4:a highly replication-competent,mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.Journal of virology 2006 Sep;80(l 7):8729-38.
[25]Heeney JL.Primate models for AIDS vaccine development.AIDS(London,England)1996;10 Suppl A:S115-22.
[26]Karlsson GB,Halloran M,Li J,Park IW,Gomila R,Reimann KA,et al.Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.Journal of virology 1997 Jun;71(6):4218-25.
[27]Cohen J.AIDS research.Vaccine studies stymied by shortage of animals.Science(New York,NY 2000 Feb 11;287(5455):959-60.
[28]Kanthaswamy S,Smith DG Effects of geographic origin on captive Macaca mulatta mitochondrial DNA variation.Comparative medicine 2004 Apr;54(2):193-201.
[29]Lifson JD,Rossio JL,Piatak M,Jr.,Parks T,Li L,Riser R,et al.Role of CD8(+)lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.Journal of virology 2001 Nov;75(21):10187-99.
[30]Ling B,Veazey RS,Luckay A,Penedo C,Xu K,Lifson JD,et al.SlV(mac)pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans.AIDS(London,England)2002 Jul 26;16(11):1489-96.
[31]Kourtis AP,Ibegbu CC,Scinicariello F,Oh CY,McClure HM.SHIV-KB9 infection of rhesus monkeys does not always cause disease-contribution of host immune factors and thymic output.Virology 2002 Nov 10;303(1):47-57.
[32]Allen TM,Vogel TU,Fuller DH,Mothe BR,Steffen S,Boyson JE,et al.Induction of AIDS virus-specific CTL activity in fresh,unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.J Immunol 2000 May l;164(9):4968-78.
[33]Gherardi MM,Ramirez JC,Esteban M.Towards a new generation of vaccines:the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens.Histology and histopathology 2001 Apr;16(2):655-67.
[34]Letvin NL.Progress in the development of an HIV-1 vaccine.Science(New York,NY 1998 Jun 19;280(5371):1875-80.
[35]McShane H.Prime-boost immunization strategies for infectious diseases.Current opinion in molecular therapeutics 2002 Feb;4(1):23-7.
[36]Malkevitch NV,Robert-Guroff M.A call for replicating vector prime-protein boost strategies in HIV vaccine design.Expert review of vaccines 2004 Aug;3(4 Suppl):S105-17.
[37]Peng B,Wang LR,Gomez-Roman VR,Davis-Warren A,Montefiori DC,Kalyanaraman VS,et al.Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Journal of virology 2005 Aug;79(16):10200-9.
[38]Bonnet MC,Tartaglia J,Verdier F,Kourilsky P,Lindberg A,Klein M,et al.Recombinant viruses as a tool for therapeutic vaccination against human cancers.Immunology letters 2000 Sep 15;74(1):11-25.
[39]Hi ll AV,Reece W,Gothard P,Moorthy V,Roberts M,Flanagan K,et al.DNA-based vaccines for malaria:a heterologous prime-boost immunisation strategy.Developments in biologicals 2000;104:171-9.
[40]Amara RR,Villinger F,Staprans SI,Altaian JD,Montefiori DC,Kozyr NL,et al.Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara(MVA)and DNA/MVA vaccines.Journal of virology 2002 Aug;76(15):7625-31.
[41]Liu Q,Li J,Yang GB,Xing H,Dai JJ,Shao YM.[Establishment of a real-time RT-PCR to detect plasma viral load of simian/human immunodeficiency virus CN97001 during its in vivo passage in rhesus monkeys].Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi =Chinese journal of experimental and clinical virology 2007 Jun;21(2):174-6.
[42]Wu Y,Hong K,Chenine AL,Whitney JB,Xu W,Chen Q,et al.Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate.Journal of medical primatology 2005 Apr,34(2):101-7.
[43]Li J,Lord CI,Haseltine W,Letvin NL,Sodroski J.Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.J Acquir Immune Defic Syndr 1992;5(7):639-46.
[44]Reimann KA,Li JT,Voss G,Lekutis C,Tenner-Racz K,Racz P,et al.An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.Journal of virology 1996 May;70(5):3198-206.
[45]Hofmann-Lehmann R,Swenerton RK,Liska V,Leutenegger CM,Lutz H,McClure HM,et al.Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load:comparison of one-versus two-enzyme systems.AIDS research and human retroviruses 2000 Sep 1;16(13):1247-57.
[46]Barnett SW,Srivastava IK,Kan E,Zhou F,Goodsell A,Cristillo AD,et al.Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.Aids 2008 Jan 30;22(3):339-48.
[47]Chenine AL,Buckley KA,Li PL,Rasmussen RA,Ong H,Jiang S,et al.Schistosoma mansoni infection promotes SHIV clade C replication in rhesus macaques.Aids 2005 Nov 4;19(16):1793-7.
[48]Horiuchi R,Akahata W,Kuwata T,Enose Y,Ido E,Suzuki H,et al.DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles.Vaccine 2006 Apr24;24(17):3677-85.
[49]Barletta JM,Edelman DC,Constantine NT.Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen.Am J Clin Pathol 2004 Jul;122(1):20-7.
[50]Manfredi R,Borderi M,Re MC,Furlini G,Monari P,Spinosa Guzman SM,et al.A comparison of immunocomplex-dissociated serum HIV-1 p24 antigenemia and plasma HIV-1 viral load:assessment of 3,129 paired assays.New Microbiol 1999 Jul;22(3):269-75.
[51]Sutthent R,Gaudart N,Chokpaibulkit K,Tanliang N,Kanoksinsombath C,Chaisilwatana P.p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection.J Clin Microbiol 2003 Mar;41(3):1016-22.
[52]Giorgi JV,Lyles RH,Matud JL,Yamashita TE,Mellors JW,Hultin LE,et al.Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.J Acquir Immune Defic Syndr 2002 Apr l;29(4):346-55.
[53]Aschbacher R,Monari P,Loili S,Donzelli C,Colangeli V,Vignoli M,et al.Evaluation of three different commercial procedures for quantifying human immunodeficiency virus type-1 RNA levels.New Microbiol 1999 Jan;22(1):1-9.
[54]Coste J,Montes B,Reynes J,Peeters M,Segarra C,Vendrell JP,et al.Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma.Journal of medical virology 1996 Dec;50(4):293-302.
[55]Hodara V,Monticelli A,Pampuro S,Salomon H,Jauregui Rueda H,Libonatti O.HIV-1 viral load: comparative evaluation of three commercially available assays in Argentina.Acta Physiol Pharmacol Ther Latinoam 1998;48(2):107-13.
[56]Leutenegger CM,Higgins J,Matthews TB,Tarantal AF,Luciw PA,Pedersen NC,et al.Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA.AIDS research and human retroviruses 2001 Feb 10;17(3):243-51.
[57]Joag SV,Li Z,Foresman L,Stephens EB,Zhao L J,Adany I,et al.Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.Journal of virology 1996May;70(5):3189-97.
[58]Luciw PA,Pratt-Lowe E,Shaw KE,Levy JA,Cheng-Mayer C.Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses(SHIV).Proceedings of the National Academy of Sciences of the United States of America 1995 Aug 1;92(16):7490-4.
[59]Ten Haaft P,Verstrepen B,Uberla K,Rosenwirth B,Heeney J.A pathogenic threshold of virus load defined in simian immunodeficiency virus-or simian-human immunodeficiency virus-infected macaques.Journal of virology 1998 Dec;72(12):10281-5.
[60]Herbeck JT,Nickle DC,Learn GH,Gottlieb GS,Curlin ME,Heath L,et al.Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host.Journal of virology 2006Feb;80(4):1637-44.
[61]Liang H,Wei M,Chert Z,Xing H,Zhao QB,Feng Y,et al.[Sequence variation in the env V3-V4 region of HIV type 1 predominant subtype B and C strains circulating in China].Zhonghua shi yan he iin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology 2003 Jun;17(2):153-8.
[62]Nowak MA,Anderson RM,McLean AR,Wolfs TF,Goudsmit J,May RM.Antigenic diversity thresholds and the development of AIDS.Science(New York,NY 1991 Nov 15;254(5034):963-9.
[63]Harouse JM,Gettie A,Tan RC,Blanchard J,Cheng-Mayer C.Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.Science(New York,NY 1999 Apr 30;284(5415):816-9.
[64]Shankarappa R,Margolick JB,Gange S J,Rodrigo AG,Upchurch D,Farzadegan H,et al.Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type I infection.Journal of virology 1999 Dec;73(l 2):10489-502.
[65]Chackerian B,Rudensey LM,Overbaugh J.Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.Journal of virology 1997 Oct;71(10):7719-27.
[66]Bergstrom CT,McEihany P,Real LA.Transmission bottlenecks as determinants of virulence in rapidly evolving pathogens.Proceedings of the National Academy of Sciences of the United States of America 1999Apt 27;96(9):5095-100.
[67]Eigen M.On the nature of virus quasispecies.Trends in microbiology 1996 Jun;4(6):216-8.
[68]Meyerhans A,Cheynier R,Albert J,Seth M,Kwok S,Sninsky J,et al.Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.Cell 1989 Sep 8;58(5):901-10.
[69]Liu SL,Rodrigo AG,Shankarappa R,Learn GH,Hsu L,Davidov O,et al.HIV quasispecies and resampling.Science(New York,NY 1996 Jul 26;273(5274):415-6.
[70]Manrubia SC,Escarmis C,Domingo E,Lazaro E.High mutation rates,bottlenecks,and robustness of RNA viral quasispecies.Gene 2005 Mar 14;347(2):273-82.
[71]Learn GH,Muthui D,Brodie SJ,Zhu T,Diem K,Mullins JI,et al.Virus population homogenization following acute human immunodeficiency virus type 1 infection.Journal of virology 2002Dec;76(23):11953-9.
[72]Mellors JW,Munoz A,Giorgi JV,Margolick JB,Tassoni C J,Gupta P,et al.Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection.Annals of internal medicine 1997 Jun 15;126(12):946-54.
[73]Mellors JW,Rinaldo CR,Jr.,Gupta P,White RM,Todd JA,Kingsley LA.Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.Science(New York,NY 1996 May 24;272(5265):1167-70.
[74]Shearer WT,Quinn TC,LaRussa P,Lew JF,Mofenson L,Almy S,et al.Viral load and disease progression in infants infected with human immunodeficiency virus type 1.Women and Infants Transmission Study Group.The New England journal of medicine 1997 May 8;336(19):1337-42.
[75]Rasmussen RA,Ong H,Song R,Chenine AL,Ayash-Rashkovsky M,Hu SL,et al.Efficacy of a multigenic protein vaccine containing multimeric HIV gpl60 against heterologous SHIV clade C challenges.AIDS (London,England) 2007 Sep 12;21(14):1841-8.
[76]Ganeshan S,Dickover RE,Korber BT,Bryson Y J,Wolinsky SM.Human immunodeficiency virus type 1genetic evolution in children with different rates of development of disease.Journal of virology 1997Jan;71(1):663-77.
[77]Wolinsky SM,Korber BT,Neumarm AU,Daniels M,Kunstman K J,Whet,ell AJ,et al.Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.Science(New York,NY 1996Apr 26;272(5261):537-42.
[78]Mani I,Gilbert P,Sankale JL,Eisen G,Mboup S,Kanki PJ.Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection.Journal of virology 2002Nov;76(21):10745-55.
[79]Choisy M,Woelk CH,Gucgan JF,Robertson DL.Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes.Journal of virology 2004 Feb;78(4):1962-70.
[80]Derdeyn CA,Decker JM,Bibollet-Ruche F,Mokili JL,Muldoon M,Denham SA,et al.Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.Science(New York,NY 2004 Mar 26;303(5666):2019-22.
[81]Chen W,Helenius J,Braakman I,Helenius A.Cotranslational folding and calnexin binding during glycoprotein synthesis.Proceedings of the National Academy of Sciences of the United States of America 1995 Jul 3;92(14):6229-33.
[82]Wei X,Decker JM,Wang S,Hui H,Kappes JC,Wu X,et al.Antibody neutralization and escape by HIV-1.Nature 2003 Mar 20;422(6929):307-12.
[83]Hofinann-Lehmann R,Vlasak J,Chenine AL,Li PL,Baba TW,Montefiori DC,et al.Molecular evolution of human immunodeficiency virus env in humans and monkeys:similar patterns occur during natural disease progression or rapid virus passage.Journal of virology 2002 May;76(10):5278-84.
[84]Oelrichs RB,Shrestha IL,Anderson DA,Deacon NJ.The explosive human immunodeficiency virus type 1epidemic among injecting drug users of Kathmandu,Nepal,is caused by a subtype C virus of restricted genetic diversity.Journal of virology 2000 Feb;74(3):1149-57.
[85]Zhang H,Hoffmann F,He.I,He X,Kankasa C,Ruprecht R,et al.Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.Retrovirology 2005;2:67.
[86]Reimann KA,Watson A,Dailey PJ,Lin W,Lord CI,Steenbeke TD,et al.Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.Virology 1999 Mar 30;256(1):15-21.
[87]Ellenberger D,Otten RA,Li B,Aidoo M,Rodriguez IV,Sariol CA,et al.HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.Virology 2006Aug 15;352(1):216-25.
[88]Kyes RC,Iones-Engel L,Chalise MK,Engel G,Heidrich J,Grant R,et al.Genetic characterization of rhesus macaques(Macaca mulatta) in Nepal.American.journal of primatology 2006 May;68(5):445-55.
[89]Trichel AM,Rajakumar PA,Murphey-Corb M.Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque.Journal of medical primatology 2002 Aug;31(4-5):171-8.
[90]Pal R,Venzon D,Letvin NL,Santra S,Montefiori DC,Miller NR,et aL ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class 1(A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.Journal of virology 2002 Jan;76(1):292-302.
[91]Muhl T,Krawczak M,Ten Haafi P,Hunsmann G,Sauermann U.MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys.J Immunol 2002 Sep 15;169(6):3438-46.
[92]Vogel T,Norley S,Beer B,Kurth R.Rapid screening for Mamu-Al-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay.Immunology 1995 Mar;84(3):482-7.
[93]Lafont BA,Buckler-White A,Plishka R,Buckler C,Martin MA.Pig-tailed macaques(Macaca nemestrina)possess six MHC-E families that are conserved among macaque species:implication for their binding to natural killer receptor variants.Immunogenetics 2004 Jun;56(3):142-54.
[94]Karlsson GB,Halloran M,Schenten D,Lee J,Racz P,Tenner-Racz K,et al.The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques.The Journal of experimental medicine 1998 Sop 21;188(6):1159-71.
[95]Ruprecht RM,Baba TW,Rasmussen R,Hu Y,Sharma PL.Murine and simian retrovirus models:the threshold hypothesis.AIDS(London,England) 1996;10 Suppl A:S33-40.
[96]Kaneyasu K,Kita M,Ohkura S,Yamamoto T,Ibuki K,Enose Y,et al.Protective efficacy of nonpathogenic nef-deleted SHIV vaccination combined with recombinant IFN-gamma administration against a pathogenic SHIV challenge in rhesus monkeys.Microbiology and immunology 2005;49(12):1083-94.
[97]Geleziunas R,Bout S,Wainberg MA.Cell surface down-modulation of CD4 after infection by HIV-1.Faseb J 1994 Jun;8(9):593-600.
[98]Gottlieb GS,Nickle DC,Jonson MA,Wong KG,Kaslow RA,Shepherd JC,et al.HIV type 1 superinfecfion with a dual-tropic virus and rapid progression to AIDS:a case report.Clin Infect Dis 2007 Aug 15;45(4):501-9.
[99]Hu SL,Travis BM,Stallard V,Abrams K,Misher L,Moran P,et al.Immune responses to SIVnme envelope glycoproteins protect macaques from homologous SIV infection.AIDS research and human retrovirnses 1992Aug;8(8):1489-94.
[100]Polacino PS,Stallard V,Klaniecki JE,Pennathur S,Montefiori DC,Langlois AJ,et al.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVnme in protection against homologous cloned and uncloned virus challenge in Macaques.Journal of virology 1999Oct;73(10):8201-15.
[101]Estcourt M J,Ramsay A J,Brooks A,Thomson SA,Medveckzy C J,Ramshaw IA.Prime-boost immunization generates a high frequency,high-avidity CDS(+) cytotoxic T lymphocyte population.International immunology 2002 Jan;14(I ):31-7.
[102]Schneider J,Gilbert SC,Hannah CM,Degano P,Prienr E,Sheu EG,et al.Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.Immunological reviews 1999 Aug;170:29-38.
[103]Amara RR,Smith JM,Staprans SI,Montefiori DC,Villinger F,Altman JD,et al.Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.Journal of virology 2002 Jun;76(12):6138-46.
[104]Amara RR,Villinger F,Altrnan JD,Lydy SL,O'Neil SP,Staprans SI,et al.Control ofa mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.Science(New York,NY 2001 Apr 6;292(5514):69-74.
[105]Barouch DH,Kunstman J,Glowczwskie J,Kunstman KJ,Egan MA,Peyerl FW,et al.Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys.Journal of virology 2003 Jul;77(13):7367-75.
[106]Doria-Rose NA,Ohlen C,Polacino P,Pierce CC,Hensel MT,Kuller L,et al.Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.Journal of virology 2003 Nov;77(21):11563-77.
[107]Fanales-Belasio E,Cafaro A,Cara A,Negri DR,Fiorelli V,Butto S,et al.HIV-1 Tat-based vaccines:from basic science to clinical trials.DNA and cell biology 2002 Sep;21(9):599-610.
[108]Shiver JW,Fu TM,Chen L,Casimiro DR,Davies ME,Evans RK,et al.Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.Nature 2002 Jan 17;415(6869):331-5.
[109]Shiver JW,Perry HC,Davies ME,Freed DC,Liu MA.Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.Annals of the New York Academy of Sciences 1995 Nov 27;772:198-208.
[110]Graham BS.Clinical trials of HIV vaccines.Annual review of medicine 2002;53:207-21.
[111]Gomez-Roman VR,Patterson LJ,Venzon D,Liewehr D,Aldrich K,Florese R,et al.Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.J Immuno12005 Feb 15;174(4):2185-9.
[112]Smith SM,Holland B,Russo C,Dailey PJ,Marx PA,Connor RI.Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV:predictive value for disease progression.AIDS research and human retroviruses 1999 Dec 10;15(18):1691-701.
[113]Cohen J.AIDS research.Promising AIDS vaccine's failure leaves field reeling.Science(New York,NY 2007 Oct 5;318(5847):28-9.
[114]Fontencau JF,Larsson M,Bhardwaj N.Interactions between dead cells and dendritic ceils in the induction of antiviral CTL responses.Current opinion in immunology 2002 Aug;14(4):471-7.
[115]Vogcls R,Zuijdgccst D,van Rijnsocvcr R,Hartkoorn E,Damen I,dc Bcthunc MP,et al.Replication-deficient human adenovirus type 35 vectors for gcnc transfer and vaccination:efficient human cell infection and bypass of preexisting adenovirus immunity.Journal of virology 2003 Aug;77(15):8263-71.
[116]TruckenmiIler ME,Norbury CC.Viral vectors for inducing CD8+ T cell responses.Expert opinion on biological therapy 2004 Jun;4(6):861-8.
[117]Wang B,Norbury CC,Greenwood R,Bermink JR,Ycwdcll JW,Frelingcr JA.Multiple paths for activation of naive CD8+ T ceils:CD4-independent help.J Immunol 2001 Aug 1;167(3):1283-9.
[118]Santra S,Barouch DH,Korioth-Schmitz B,Lord CI,Krivulka GR,Yu F,ctal.Recombinant poxvirus boosting of DNA-primcd rhesus monkeys augments peak but not memory T lymphocyte responses.Proceedings of the National Academy of Sciences of the United States of America 2004 Jul 27;101(30):11088-93.
[119]Stamatatos L,Davis D.New insights into protective humoral responses and HIV vaccines.Aids 2001;15Suppl 5:S105-15.
[120]Cao H,Kanki P,Sankale JL,Dieng-Sarr A,Mazzara GP,Kalams SA,ctal.Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades:implications for vaccine development.Journal of virology 1997 Nov;71(11):8615-23.
[121]McAdam S,Kaleebu P,Krausa P,Goulder P,French N,Collin B,eta!.Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection.Aids 1998 Apr 16;12(6):571-9.
[122]Nakamura Y,Kameoka M,Tobiume M,Kaya M,Ohki K,Yamada T,et al.A chain section containing epitopes for cytotoxic T,B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein.Vaccine 1997 Apt;15(5):489-96.
[123]Nishimura Y,Igarashi T,Haigwood NL,Sadjadpour IL Donau OK,Buckler C,et al.Transfer of neutralizing IgG to macaques 6 h but not 24 h aRer SHIV infection confers sterilizing protection:implications for HIV-1vaccine development.Proceedings of the National Academy of Sciences of the United States of America 2003 Dec 9;100(25):15131-6.
[124]Kaech SM,Ahmed R.Memory CD8+ T cell differentiation:initial antigen encounter triggers a developmental program in naive cells.Nature immunology 2001 May;2(5):415-22.
[125]Feinberg MB,Moore JP.AIDS vaccine models:challenging challenge viruses.Nature medicine 2002Mar;8(3):207-10.
[126]Barouch DH,Santra S,Schmitz JE,Kuroda M J,Fu TM,Wagner W,et al.Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.Science(New York,NY 2000Oct 20;290(5491):486-92.
[127]Earl PL,Wyatt LS,Montefiori DC,Bilska M,Woodward R,Markham PD,et al.Comparison of vaccine strategies using recombinant cnv-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.Virology 2002 Mar 15;294(2):270-81.
[1]McCormick-Davis C,Zhao LJ,Mukherjcc S,et al.Chronology of genetic changes in the vpu,env,and Ncf genes of chimeric simian-human immunodcficiency virus(strain HXB2) during acquisition of virulence for pig-tailed macaques.Virology.1998 Sep 1;248(2):275-83.
[2]Shibata R,Sakai H,Kiyomasu T,ctal.Gcncration and characterization of infectious chimeric clones between human immunodcficiency virus type 1 and simian immunodeficiency virus from an Aft-lean green monkey.J Virol.1990 Dcc;64(12):5861-68.
[3]Kuwata T,Takcmura T,Takchisa J,ctal.Infection of macaques with chimeric simian and human immunodcficicncy viruses containing Env from subtype F.Arch Virol.2002Jun;147(6):1121-32.
[4]Himathongkhana S,Douglas GC,Fang A,ct al.Species tropism of chimeric SHIV clones containing HIV-1 subtypc-A and subtypc-E envelope genes.Virology.2002 Jul 5;298(2):189-99.
[5]Shibata R,Kawamura M,Sakai H,ct al.Generation of a chimeric human and simian immunodeficiency virus infectious to monkcy peripheral blood mononuclcar cells.J Virol.1991Jui;65(7):3514-20.
[6]Luciw PA,Pratt-Lowc E,Shaw KE,Persistent infection of rhesus macaques with T-cell-line-tropic and macrophagc-tropic clones of simian/human immunodeficicncy viruses (SHIV).Proc Natl Acad Sci U S A.1995 Aug 1;92(16):7490-4.
[7]Li Jr,Halloran M,Lord CI,et al.Persistent infection of macaques with simian-human immunodcficicncy viruses.J Virol.1995 Nov;69(11):7061-7
[8]Joag SV,Li Z,Foresman L,et al.Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.J Virol.1996 May;70(5):3189-97.
[9]Durra CS,Beyer C,Kieny MP,et al.High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env,rev,tat,and vpu genes from HIV-1 Lai.Virology.1996 Sep 15;223(2):351-61
[10]Raghavan R,Stephens EB,Joag SV,et al.Neuropathogenesis of chimeric simian/human immunodeficiency virus infection in pig-tailed and rhesus macaques.Brain Pathol.1997Jul;7(3):851-61
[11]Reimann KA,Li JT,Veazey R,et al.A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.J Virol.1996 Oct;70(10):6922-8
[12]Reimann KA,Li JT,Voss G,et al.An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacitiy to a chimeric simian/human immunodeficiency virus in rhesus monkeys.J Virol.1996 May;70(5):3198-206
[13]Ranjbar S,Jones S,Stott EJ,et al.The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates.AIDS Res Hum Retroviruses.1997 Jun 10;13(9):797-800.
[14]Bogers WM,Dubbes R,ten Haaft P,et al.Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta.Virology.1997 Sep 15;236(1):110-7
[15]Narayan SV,Mukherjee S,Jia F,et al.Characterization of a neutralization-escape variant of SHIVKU-1,a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.Virology.1999 Mar 30;256(1):54-63.
[16]Lin ZQ,Muhkerjee S,Sahni M,et al.Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS,neurological disease,and renal disease in rhesus macaques.Virology.1999 Aug 1;260(2):295-307
[17]Chen Z,Huang Y,Zhao X,et al.Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques(Macaca nemestrina).J Virol.2000 Jul;74(14):6501-10.
[18]Ndung'u T,Lu Y,Renjifo B,et al.Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate:rhesus macaque model.J Virol.2001 Dec;75(23):11417-25.
[19]Cayabyab M,Rohne D,Pollakis G,et al.Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate.AIDS Res Hum Retroviruses.2004 Jan;20(1):27-40.
[20]Wu Y,Hong K,Chenine AL,et al.Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate.J Med Primatol.2005 Apr;34(2):101-7
[21]Kaizu M,Sato H,Ami Y,et al.Infection of macaques with an R5-tropic SHIV bearing a chimeric envelope carrying subtype E V3 loop among subtype B framework.Arch Virol.2003 May;148(5):973-88.
[22]Ranjbar S,Bhattacharya U,Oram J,et al.Construction of infectious SIV/HIV-2 chimeras.AIDS.2000 Nov 10;14(16):2479-84.
[23]Balzarini J,Weeger M,Camarasa MJ,et al.Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1(HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors.Biochem Biophys Res Commun.1995 Jun 26;211(3):850-6
[24]Uberla K,Stahl-Hennig C,Bottiger D,et al.Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.Proc Natl Acad Sci U S A.1995 Aug 29;92(18):8210-4
[25]Akiyama H,Ido E,Akahata W,et al.Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type l.J Gen Virol.2003 Jul;84(Pt 7):1663-9
[26]Ambrose Z,Boltz V,Palmer S,et al.In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus(HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.J Virol.2004 Dec;78(24):13553-61.
[27]Kozyrev IL,Miura T,Takemura T,et al.Co-expression of interleukin-5 influences replication of simian/human immunodeficiency viruses in vivo.J Gen Virol.2002 May;83(Pt 5):1183-8.
[28]Kozyrev IL,Miura T,Haga T,et al.Construction of SIV/HIV-I chimeric viruses having the IL-5gene and determination of their ability to replicate and produce IL-5.Arch Virol.2001;146(6):1051-62
[29]Haga T,Shimizu Y,Okoba M,et al.Construction and in vitro properties of chimeric simian and human immunodeficiency virus with the human TNF-alpha gene.Microbiol Immunol.2002;46(12):849-55.
[30]Iida T,Kuwata T,Ui M,et al.Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma.Arch Virol.2004 Apr;149(4):743-57.Epub 2003 Dec 8.
[31]Haga T,Okoba M,Yamazaki N,et al.Characterization ofvpr vector constructed from chimeric simian and human immunodeficiency virus.J Vet Med Sci.2003 May;65(5):633-6.
[32]Hout DR,Gomez ML,Pacyniak E,et al.Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus(SHIV(KU1bMC33)) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques.Virology.2005 Sep 28
[33]Shimizu Y,Okoba M,Yamazald N,et al.Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene.Microbes Infect.2005
[34]Shimizu Y,Miyazaki Y,Ibuki K,et al.Induction of immune response in macaque monkeys infected with simian-human immunodeficiency virus having the TNF-alpha gene at an early stage of infection.Virology.2005 Sep 15
[35]Bertsch C,Cluet D,Beyer C,et al.Properties of a chimeric simian-human immunodeficiency virus expressing an hybrid HIV-1 Nef/SIVmac Nef protein.Arch Virol.2002,147(10):1963-75.
[36]Singh DK,McCormick C,Pacyniak E,et al.Pathogenic and nef-interrupted simian-human immunodeficiency viruses traffic to the macaque CNS and cause astrocytosis early after inoculation.Virology.2002 Apt 25;296(1):39-51.
[37]Buch S,Pinson D,King CL,et al.Inhibitory and enhancing effects of IFN-r and IL-4 on SHIV KU replication in rhesus macaque rnacrophages:correlation between TH2 cytokines and productive infection in tissue macrophages during late-stage infection.
[38]Igarashi T,Donau OK,Imamichi H,et al.Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4,not CCR5,for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages.J Virol.2003 Dec;77(24):13042-52.
[39]Lu Y,Brosio P,Lafaile M,et al.Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques.J Virol.1996 May;70(5):3045-50
[40]Joag SV,Li Z,Foresman L,et al.Chimeric simian/human immunodeficiency virus that causes progressive loss ofCD4+ T cells and AIDS in pig-tailed macaques.J Virol.1996,70(5):3189-97.
[41]Stephens EB,Mukherjee S,Sahni M,et al.A cell-free stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed macaques has a limited number of amino acid substitutions in both SIVmac and HIV-1 regions of the genome and has offered cytotropism.Virology.1997 May 12;231(2):313-21.
[42]Cayabyab M,Karlsson GB,Etemad-Moghadam BA,et al.Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus(SHIV-HXBc2).J Virol.1999 Feb;73(2):976-84.
[43]Song B,Cayabyab M,Phan N,et al.Neutralization sensitivity of a simian-human immunodeficiency virus(SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.Virology.2004 Apr 25;322(1):168-81.
[44]Karlsson GB,Halloran M,Li J,et al.Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.J Virol.1997 Jun;71(6):4218-25
[45]Song R J,Chenine A L,Rasmussen R A,et al.Molecularly Cloned SHIV-1157ipd3N4:a Highly Replication-Competent,Mucosally Transmissible R5 Simian-Human Immunodeficiency Virus Encoding HIV Clade C env.J Virol.2006 Sep;80(17):8729-38
[46]Balfe P,Shapiro S,Hsu M,et al.Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques
[47]Matano T,Shibata R,Siemon C,et al.Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques.J Virol.1998 Jan;72(1):164-9
[48]Seaman MS,Santra S,Newberg MH,et al.Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A~*01-associated control of s/m/an/human immunodeficiency virus 89.6P replication in rhesus monkeys.J Virol.2005 Apr;79(8):4580-8
[49]Zhang ZQ,Fu TM,Casimiro DR,et al.Mamu-A~*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection.J Virol.2002,76(24):12845-54.
[50]Ahmed RK,Makitalo B,Karlen K,et al.Spontaneous production of R.ANTES and antigenspecific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge.Clin Exp Immunol.2002 Jul;129(1):11-8.
[51]Wallace M,Waterman PM,Mitchen/L,et al.Lymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques.J Virol.1999,73(12):10236-44.
[52]Kumar R,Torres C,Yamamura Y,et al.Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus.J Virol.2004 Oct;78(20):11425-8.
[53]Kumar R,Perez-Casanova AE,Tirado G,et al.Increased viral replication in simian immunodeficiency virus/simian-HIV-infected macaques with self-administering model of chronic alcohol consumption.J Acquir Immune Defic Syndr.2005 Aug 1;39(4):386-90
[54]Suzuki H,Motohara M,Miyake A,et al.Intrathymic effect of acute pathogenic SHIV infection on T-lineage cells in newborn macaques.Microbiol Immunol.2005;49(7):667-79
[55]Sui Y,Li S,Pinson D,et al.Simian human immtmodeficiency virus-associated pneumonia correlates with increased expression of MCP-1,CXCL10,and viral RNA in the lungs of rhesus macaques.Am J Pathol.2005 Feb;166(2):355-65
[56]Endo Y,Igarashi T,Nishimura Y,et al.Short-and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.J Virol.2000 Aug;74(15):6935-45.
[57]ten Haaft P,Almond N,Biberfeld G,et al.Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection.J Med Primatol.2001 Aug;30(4):207-14.
[58]Ui M,Kuwata T,Igarashi T,et al.Protective immunity of gene-deleted SHIVs having an HIV-1Env against challenge infection with a gene-intact SHIV.J Med Primatol.1999,28(4-5):242-8
[59]Ui M,Kuwata T,Igarashi T,et al.Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.Virology.1999 Dec 20;265(2):252-63
[60]Kumar A,Lifson JD,Li Z,Jia F,et al.Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).Virology.2001 Jan 5;279(1):241-56.
[61]Rosenwirth B,Bogers WM,Nieuwenhuis IG,et al.An anti-HIV strategy combining chemotherapy and therapeutic vaccination.J Med Primatol.1999 Aug-Oct;28(4-5):195-205.
[62]Smith MS,Foresman L,Lopez G J,Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine]treatment on SHIV(KU2) infection of rhesus macaques.Virology.2000 Nov 25;277(2):306-15
[63]Veazey RS,Klasse PJ,Schader SM,et al.Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.Nature.2005 Nov 3;438(7064):99-102.
[64]Dhillon NK,Sui Y,Potula R,et al.Inhibition of pathogenic SHIV replication in macaques treated with antisense DNA of interleuldn-4.Blood.2005 Apt 15;105(8):3094-9.Epub 2004 Dec 23